Literature DB >> 33742120

Hepatic stellate cells promote intrahepatic cholangiocarcinoma progression via NR4A2/osteopontin/Wnt signaling axis.

Chu-Yu Jing1, Yi-Peng Fu2, Cheng Zhou1,3, Mei-Xia Zhang4, Yong Yi1,3, Jin-Long Huang1,3, Wei Gan1,3, Juan Zhang1, Su-Su Zheng1, Bo-Heng Zhang5,6, Shuang-Jian Qiu7,8.   

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a highly fatal malignancy characterized by a vast amount of intra-tumoral fibroblasts. These fibroblasts are potentially implicated in maintaining the high aggressiveness of ICC, whereas its pro-cancer mechanisms remain scarcely reported. Here, by establishing co-culture models of ICC cells and hepatic stellate cells (HSCs), we identified that HSCs triggered the expression of nuclear receptor family 4 subgroup A member 2 (NR4A2), a transcription factor previously reported as a molecular switch between inflammation and cancer, in ICC cells. Functionally, NR4A2 promotes tumor proliferation, metastatic potentiality and represents an independent prognostic indicator for overall survival in ICC patients. Mechanistically, NR4A2 upregulates osteopontin (OPN) expression through transcriptional activation and thereby augments the activity of Wnt/β-catenin signaling. Intriguingly, in the context of co-culture, vascular endothelial growth factor (VEGF), a previously proved NR4A2 stimulus, not only enhances NR4A2 expression, but also can be blunted by the interference of the NR4A2-OPN axis. Altogether, this study suggests the NR4A2/OPN/Wnt signaling axis to be a pivotal executor of HSC-instigated cancer-promoting roles in ICC, and the NR4A2/OPN/VEGF positive feedback loop may help to reinforce the effect.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33742120     DOI: 10.1038/s41388-021-01705-9

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

1.  Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.

Authors:  John N Primrose; Richard P Fox; Daniel H Palmer; Hassan Z Malik; Raj Prasad; Darius Mirza; Alan Anthony; Pippa Corrie; Stephen Falk; Meg Finch-Jones; Harpreet Wasan; Paul Ross; Lucy Wall; Jonathan Wadsley; Jeff T R Evans; Deborah Stocken; Raaj Praseedom; Yuk Ting Ma; Brian Davidson; John P Neoptolemos; Tim Iveson; James Raftery; Shihua Zhu; David Cunningham; O James Garden; Clive Stubbs; Juan W Valle; John Bridgewater
Journal:  Lancet Oncol       Date:  2019-03-25       Impact factor: 41.316

2.  Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.

Authors:  John Bridgewater; Peter R Galle; Shahid A Khan; Josep M Llovet; Joong-Won Park; Tushar Patel; Timothy M Pawlik; Gregory J Gores
Journal:  J Hepatol       Date:  2014-03-27       Impact factor: 25.083

Review 3.  The biology and function of fibroblasts in cancer.

Authors:  Raghu Kalluri
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

4.  MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis.

Authors:  Benjamin G Cuiffo; Antoine Campagne; George W Bell; Antonio Lembo; Francesca Orso; Evan C Lien; Manoj K Bhasin; Monica Raimo; Summer E Hanson; Andriy Marusyk; Dorraya El-Ashry; Peiman Hematti; Kornelia Polyak; Fatima Mechta-Grigoriou; Odette Mariani; Stefano Volinia; Anne Vincent-Salomon; Daniela Taverna; Antoine E Karnoub
Journal:  Cell Stem Cell       Date:  2014-10-16       Impact factor: 24.633

5.  Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.

Authors:  Paola Bertuccio; Matteo Malvezzi; Greta Carioli; Dana Hashim; Paolo Boffetta; Hashem B El-Serag; Carlo La Vecchia; Eva Negri
Journal:  J Hepatol       Date:  2019-03-23       Impact factor: 25.083

6.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Authors:  Chih-Hao Chang; Jing Qiu; David O'Sullivan; Michael D Buck; Takuro Noguchi; Jonathan D Curtis; Qiongyu Chen; Mariel Gindin; Matthew M Gubin; Gerritje J W van der Windt; Elena Tonc; Robert D Schreiber; Edward J Pearce; Erika L Pearce
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

Review 7.  Combination cancer immunotherapies tailored to the tumour microenvironment.

Authors:  Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

8.  Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas.

Authors:  Bernard Paule; Marie-Olga Herelle; Estelle Rage; Michel Ducreux; René Adam; Catherine Guettier; Marie-Pierre Bralet
Journal:  Oncology       Date:  2007-11-15       Impact factor: 2.935

Review 9.  A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.

Authors:  Miguel F Sanmamed; Lieping Chen
Journal:  Cell       Date:  2018-10-04       Impact factor: 41.582

10.  Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.

Authors:  Supriya K Saha; Andrew X Zhu; Charles S Fuchs; Gabriel A Brooks
Journal:  Oncologist       Date:  2016-03-21
View more
  4 in total

1.  Nurr1 Is Not an Essential Regulator of BDNF in Mouse Cortical Neurons.

Authors:  Mona Abdollahi; Margaret Fahnestock
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

2.  NOV/CCN3 Promotes Cell Migration and Invasion in Intrahepatic Cholangiocarcinoma via miR-92a-3p.

Authors:  Tingming Liang; Lulu Shen; Yaya Ji; Lin Jia; Yuyang Dou; Li Guo
Journal:  Genes (Basel)       Date:  2021-10-21       Impact factor: 4.096

3.  Expression profiling suggests the involvement of hormone-related, metabolic, and Wnt signaling pathways in pterygium progression.

Authors:  Jiarui Li; Tianchang Tao; Yingying Yu; Ningda Xu; Wei Du; Mingwei Zhao; Zhengxuan Jiang; Lvzhen Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-14       Impact factor: 6.055

4.  TMEM88 Modulates Lipid Synthesis and Metabolism Cytokine by Regulating Wnt/β-Catenin Signaling Pathway in Non-Alcoholic Fatty Liver Disease.

Authors:  Huan Zhou; Xingyu Zhu; Yan Yao; Yue Su; Jing Xie; Minhui Zhu; Cuixia He; Jiaxiang Ding; Yuanyuan Xu; Rongfang Shan; Ying Wang; Xiangdi Zhao; Yuzhou Ding; Bingyan Liu; Zhonghuan Shao; Yuanyuan Liu; Tao Xu; Yunqiu Xie
Journal:  Front Pharmacol       Date:  2022-01-04       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.